SV2010003660A - Conjugados antagonistas peptidicos analogos a la bombesina - Google Patents

Conjugados antagonistas peptidicos analogos a la bombesina

Info

Publication number
SV2010003660A
SV2010003660A SV2010003660A SV2010003660A SV2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A
Authority
SV
El Salvador
Prior art keywords
bomb
analogs
peptidic antagonist
antagonist conjugates
peptidic
Prior art date
Application number
SV2010003660A
Other languages
English (en)
Inventor
Helmut Maecke
Jean Claude Reubi
Rosalba Mansi
Original Assignee
Universitaetsspital Basel
Univ Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39677415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2010003660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitaetsspital Basel, Univ Bern filed Critical Universitaetsspital Basel
Publication of SV2010003660A publication Critical patent/SV2010003660A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14Peptides being immobilised on, or in, an inorganic carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN MEDICAMENTO DE DIAGNÓSTICO Y TERAPÉUTICO QUE COMPRENDE UN CONJUGADO ANTAGONISTA PEPTÍDICO ANÁLOGO A LA BOMBESINA QUE TIENE LA FORMULA GENERAL (I), DONDE A ES UN QUELANTE DE METALES QUE COMPRENDE AL MENOS UN RADIONUCLEIDO METÁLICO, B ES UN SEPARADOR UNIDO AL EXTREMO N DE C, O UN ENLACE COVALENTE, Y C ES UN ANTAGONISTA PEPTÍDICO ANÁLOGO A LA BOMBESINA QUE TIENE UNA SECUENCIA COMO LA REIVINDICADA, DONDE ADEMÁS, X ES UN NUMERO ENTERO ENTRE 1 Y 3, Y N ES UN NÚMERO ENTERO ENTRE 1 Y 6(I) [A-(B)N]X-C (FIG. 1)
SV2010003660A 2008-03-07 2010-09-07 Conjugados antagonistas peptidicos analogos a la bombesina SV2010003660A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08075180A EP2100900A1 (en) 2008-03-07 2008-03-07 Bombesin analog peptide antagonist conjugates

Publications (1)

Publication Number Publication Date
SV2010003660A true SV2010003660A (es) 2011-02-17

Family

ID=39677415

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003660A SV2010003660A (es) 2008-03-07 2010-09-07 Conjugados antagonistas peptidicos analogos a la bombesina

Country Status (32)

Country Link
US (2) US9035023B2 (es)
EP (2) EP2100900A1 (es)
JP (1) JP5784911B2 (es)
KR (2) KR20160128425A (es)
CN (1) CN101965358B (es)
AR (1) AR070809A1 (es)
AU (1) AU2009221204C1 (es)
BR (1) BRPI0909823B1 (es)
CA (1) CA2717427C (es)
CL (1) CL2009000537A1 (es)
CO (1) CO6290707A2 (es)
CR (1) CR11671A (es)
CY (1) CY1118687T1 (es)
DK (1) DK2252628T3 (es)
DO (1) DOP2010000269A (es)
EC (1) ECSP10010467A (es)
ES (1) ES2615805T3 (es)
HU (1) HUE032980T2 (es)
MX (1) MX2010009843A (es)
NZ (1) NZ587795A (es)
PA (1) PA8818501A1 (es)
PE (1) PE20091753A1 (es)
PL (1) PL2252628T3 (es)
PT (1) PT2252628T (es)
RU (1) RU2523531C2 (es)
SI (1) SI2252628T1 (es)
SV (1) SV2010003660A (es)
TW (1) TWI515011B (es)
UA (1) UA103314C2 (es)
UY (1) UY31693A (es)
WO (1) WO2009109332A1 (es)
ZA (1) ZA201006385B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
MX2013005697A (es) * 2010-11-22 2014-08-01 Piramal Imaging Sa Analogos de bombesina marcados con lutecio 177, para radioterapia.
EP2710027A1 (en) * 2011-05-19 2014-03-26 Universitätsspital Basel Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
CA2886068C (en) 2012-09-25 2021-06-22 Advanced Accelerator Applications Usa, Inc. Radiolabeled grpr-antagonists for diagnostic imaging and treatment of grpr-positive cancer
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
WO2014164988A1 (en) * 2013-03-13 2014-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
WO2015119763A1 (en) * 2014-02-06 2015-08-13 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
AU2014396468B2 (en) 2014-06-06 2019-02-21 Technische Universitat Munchen Modified cyclopentapeptides and uses thereof
CN106794264B (zh) 2014-06-10 2021-03-23 3B制药有限公司 包含神经降压肽受体配体的缀合物及其用途
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
US20160022785A1 (en) 2014-06-16 2016-01-28 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
CN104610431B (zh) * 2014-11-26 2017-12-15 南京市第一医院 一种多肽及其应用
JP2019504011A (ja) 2015-12-16 2019-02-14 ネプエトゥクス,エルエルシー グルテン不耐症およびそれにより発生する障害を治療するための組成物および方法
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
US11241511B2 (en) 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
SI3568205T1 (sl) 2017-01-12 2023-12-29 Radiomedix Inc. Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
JP2022541752A (ja) 2019-07-08 2022-09-27 3ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
WO2021250240A1 (en) 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP3973999A1 (en) * 2020-09-28 2022-03-30 Orano Med Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
TW202340226A (zh) 2021-12-17 2023-10-16 德商3B製藥有限公司 碳酸酐酶ix配位體
WO2024052431A1 (en) 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
DE69018226T2 (de) * 1989-07-20 1995-09-21 Sandoz-Patent-Gmbh, 79539 Loerrach Markierte polypeptidderivate.
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5369094A (en) 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US6200546B1 (en) 1997-04-22 2001-03-13 The Curators Of The University Of Missouri Gastrin receptor-avid peptide conjugates
US7060247B2 (en) 1997-04-22 2006-06-13 The Curators Of The University Of Missouri Gastrin receptor-avid peptide conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
PL341762A1 (en) 1997-12-24 2001-05-07 Vertex Pharma Precursors of aspartil protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
WO2002049644A1 (en) * 2000-12-20 2002-06-27 Warner-Lambert Company Llc Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
CA2783275A1 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
WO2007109475A2 (en) 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
MX2013005697A (es) * 2010-11-22 2014-08-01 Piramal Imaging Sa Analogos de bombesina marcados con lutecio 177, para radioterapia.

Also Published As

Publication number Publication date
UY31693A (es) 2010-01-05
CN101965358A (zh) 2011-02-02
CA2717427A1 (en) 2009-09-11
WO2009109332A1 (en) 2009-09-11
UA103314C2 (ru) 2013-10-10
RU2523531C2 (ru) 2014-07-20
CO6290707A2 (es) 2011-06-20
EP2252628A1 (en) 2010-11-24
KR101734553B1 (ko) 2017-05-11
KR20160128425A (ko) 2016-11-07
DK2252628T3 (en) 2017-02-06
TW200944239A (en) 2009-11-01
US20150265733A1 (en) 2015-09-24
US20110097266A1 (en) 2011-04-28
AU2009221204C1 (en) 2016-12-08
RU2010140846A (ru) 2012-04-20
BRPI0909823B1 (pt) 2022-04-19
AU2009221204B2 (en) 2013-09-05
CY1118687T1 (el) 2017-07-12
EP2252628B1 (en) 2016-12-28
AU2009221204A1 (en) 2009-09-11
KR20110014565A (ko) 2011-02-11
US9035023B2 (en) 2015-05-19
JP5784911B2 (ja) 2015-09-24
CA2717427C (en) 2016-02-23
PE20091753A1 (es) 2009-12-13
MX2010009843A (es) 2011-03-04
PL2252628T3 (pl) 2017-07-31
CL2009000537A1 (es) 2010-07-19
NZ587795A (en) 2012-07-27
PT2252628T (pt) 2017-02-10
BRPI0909823A2 (pt) 2019-03-06
HUE032980T2 (en) 2017-11-28
DOP2010000269A (es) 2010-10-31
EP2100900A1 (en) 2009-09-16
SI2252628T1 (sl) 2017-05-31
ZA201006385B (en) 2016-10-26
ECSP10010467A (es) 2010-10-30
TWI515011B (zh) 2016-01-01
CN101965358B (zh) 2019-09-03
PA8818501A1 (es) 2010-04-21
JP2011515338A (ja) 2011-05-19
AR070809A1 (es) 2010-05-05
CR11671A (es) 2010-11-01
ES2615805T3 (es) 2017-06-08

Similar Documents

Publication Publication Date Title
SV2010003660A (es) Conjugados antagonistas peptidicos analogos a la bombesina
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CO6362017A2 (es) Peptidos antivirales terapeuticos
CA138306S (en) Display screen
CA137507S (en) Display screen
CA137509S (en) Display screen
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
CL2011000692S1 (es) Motocicleta constituida por una cubierta delantera, que presenta una mitad inferior de silueta frontal rectangular y vertices redondeados, provista de un boqueron central de perfil curvo concavo y silueta trapecial invertida de lados oblicuos curvo convexos, por donde se introduce el tapabarro y la mitad superior.
CA137508S (en) Display screen
CR10032A (es) Preparación sólida
DOP2006000049A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
AR087094A1 (es) Formulaciones que estabilizan proteinas
PE20201285A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
GT200600048A (es) Pirroles sustituidos, composiciones que los contienen, proceso de fabricación y utilización.
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
AR088031A1 (es) Articulo absorbente

Legal Events

Date Code Title Description
FD Lapse